Serge Saxonov - 23 Dec 2024 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov
Issuer symbol
TXG
Transactions as of
23 Dec 2024
Net transactions value
+$14,400
Form type
4
Filing time
23 Dec 2024, 20:29:36 UTC
Previous filing
25 Nov 2024
Next filing
26 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $14,400 +12,000 +1.4% $1.20 884,574 23 Dec 2024 Direct
holding TXG Class A Common Stock 27 23 Dec 2024 See footnote F1
holding TXG Class A Common Stock 870 23 Dec 2024 See footnote F2
holding TXG Class A Common Stock 213,250 23 Dec 2024 See footnote F3
holding TXG Class A Common Stock 22,570 23 Dec 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -12,000 -15% $0.000000 67,463 23 Dec 2024 Class A Common Stock 12,000 $1.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F2 The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
F3 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F4 The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
F5 This option, originally for 300,000 shares, of which 232,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.